2022-10-21

ROI-NJ: BD’s new Onclarity HPV test greatly improves standard of care for women

ROI-NJ: BD’s new Onclarity HPV test greatly improves standard of care for women

Molly Broache, Associate Director, Medical Affairs for US IDS explains how the BD Onclarity™ HPV Assay positively impacts public health by providing a more precise estimate of a woman’s risk of cervical precancer and cancer.

Latest resources

Discover our latest articles, webinars, press releases and updates in women's health.

A healthy and happy woman with a cellphone
Vaginitis | Brochures
BD Vaginal Panel Reimbursement and Market Access Toolkit
ReachMD: The importance of extended genotyping in cervical cancer screening: The special case of HPV 31
Cervical Cancer | Webinars & Videos
ReachMD: The importance of extended genotyping in cervical cancer screening: The special case of HPV 31
Chris Beddard, Vice President, U.S. Marketing, Integrated Diagnostic Solutions at BD
Cervical Cancer | News & Updates
NJBIZ Conversations: Chris Beddard